Beena Wood, Qinecsa, explains how AI could revolutionize pharmacovigilance, if data, trust, skills, and organizational ...
According to Dr. Jennifer Levin Carter, MD, founder and CEO of Medzown, the concept of personalized medicine shifted from a ...
Arthur Tzianabos, CEO, Lifordi Immunotherapeutics, spoke with PharmTech about the company’s immune-directed antibody-drug ...
Beena Wood, Qinecsa, saw 2025 as an AI superposition in which pharmacovigilence needed better data foundations and regulation ...
Nina Moreno, Nelson Labs, explains how rapid sterility testing is reshaping pharmaceutical quality control—cutting release ...
Saharsh Davuluri, Neuland Labs, urges API and peptide automation by 2026 to match modern biologics standards.
PharmTech recently spoke with Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs, to get his perspective on trends that shaped pharmaceutical development and manufacturing in 2025 and ...
Rare diseases, defined by FDA as “a disease or condition that affects less than 200,000 people in the United States” (1), may ...
The company’s new AI agent automates labor-intensive processes involved in trial document management.
Paolo Ferrigno Product Manager prefilled syringes and cartridges Datwyler Healthcare ...
In Episode 31, industry veteran Deborah Dunsire goes behind the headlines to discuss the current state of innovation and ...
In this part 3 of our three-part interview, Stenberg explores the evolving manufacturing paradigm in the pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback